Dr Jeffrey CummingsAcademic
University of Nevada
Cited in UK press coverage of health & social care
1 citation
Across 1 topic, first on 27 Aug 2026.
Expertise
Cited on
What they’ve said
“Anti‑amyloid medicines such as lecanemab and donanemab have been a crucial breakthrough. They've shown that directly targeting the disease's process can slow decline. But they are only the beginning of what people with Alzheimer's will ultimately need.”
University of Nevada · Dementia · 27 Aug 2026 · Slow Alzheimer’s diagnoses ‘mean UK patients missing out on experimental treatments’ ↗
Source references
- Slow Alzheimer’s diagnoses ‘mean UK patients missing out on experimental treatments’theguardian.com · 27 Aug 2026
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.